Skip to content

The FCAT

A randomized, double blind, placebo-controlled study on the effect of 3 months treatment with the analgesic tapentadol on conditioned pain modulation (CPM) and pain relief in patients with chronic pain from fibromyalgia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28585
Enrollment
40
Registered
2016-09-19
Start date
2016-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Interventions

Patients will be treated with a placebo or Tapentadol for 3 months.

Sponsors

Leiden University Medical Center (LUMC)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists class 1 and 2 patients, 18 – 75 years; BMI < 40 kg/m2. Patients need to have a pain score &#8805; 5 (on a scale of 0-10) for most of the day and meet the 2010 American College of Rheumatology diagnostic criteria. Patients need to have a absent/inactive CPM response.

Exclusion criteria

Exclusion criteria: Unable to give written informed consent; medical disease such as pulmonary, renal, liver, cardiac, gastro-intestinal, vascular disease; (iii) allergy to study medication; (iv) history of illicit drug abuse or alcohol abuse; (v) history of psychosis; (vi) epilepsy; (vii) pregnancy and/or lactation; (viii) strong opioids and benzodiazepine use. Patients are not allowed to continue co-analgesics that target CPM.

Design outcomes

Primary

MeasureTime frame
- Conditioned Pain Modulation (CPM) - Temporal summation (TS) - Offset Analgesia (OA) - Pain relief

Secondary

MeasureTime frame
- Pain Detect questionnaire - The Big Five Inventory - Profile Of Mood States - Neuropathic Pain Symptoms Inventory Questionnaire - Hospital Anxiety and Depression Scale (HADS) - C-fiber density in the cornea

Contacts

Public ContactM. Niesters

Leiden University Medical Center

m.niesters@lumc.nl071-5262301

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)